Instytut Zdrowia Dr Boczarska-Jedynak
- Address
- Ul. Gen. Jaroslawa Dabrowskiego 4, 32-600 Oświęcim, Poland
Cardiovascular Diseases
Research at Instytut Zdrowia Dr Boczarska‑Jedynak includes safety assessments of new therapies that may impact heart health, focusing on patient tolerance and long‑term vascular outcomes.
- Evaluation of anti‑inflammatory agents for vascular protection
- Monitoring cardiac safety signals in neuro‑focused trials
- Exploration of biomarkers related to blood pressure regulation
The Oświęcim site works with local cardiology units to integrate cardiovascular observations into broader clinical programs.
Immune System Diseases
The institute conducts studies on autoimmune conditions such as Psoriasis and Cutaneous Lupus Erythematosus, aiming to test novel biologics and improve disease control.
- Testing efficacy of targeted antibodies for skin inflammation
- Assessing safety of oral agents for chronic urticaria
- Investigating immune‑modulating therapies for systemic lupus manifestations
Collaborative efforts with rheumatology specialists enhance the depth of immune‑focused research at the Oświęcim centre.
Musculoskeletal Diseases
Trials address movement‑related disorders, including Cervical Dystonia and upper‑limb spasticity, to identify effective injectable and oral treatments for muscle tone regulation.
- Dose‑finding studies of botulinum toxin formulations for dystonia
- Comparative evaluation of new agents for post‑stroke spasticity
- Safety profiling of therapies targeting facial muscle prominence
The site’s physiotherapy team supports functional assessments, ensuring comprehensive outcome measurement.
Nervous System Diseases
A robust portfolio targets neurodegenerative and neurovascular conditions such as Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, and various migraine subtypes, evaluating disease‑modifying agents and symptom‑relief strategies.
- Investigating brain‑targeted compounds for early‑stage Parkinson’s
- Measuring MRI outcomes to monitor multiple sclerosis activity
- Testing preventive migraine therapies in chronic and episodic populations
- Assessing cognition‑enhancing treatments for Alzheimer’s and mild cognitive impairment
The Oświęcim research hub partners with neurology clinics to recruit participants across the disease spectrum.
Skin and Connective Tissue Diseases
Clinical work focuses on dermatologic disorders, including Psoriasis and lupus‑related skin involvement, seeking to improve lesion clearance and patient quality of life.
- Evaluating topical and systemic agents for plaque psoriasis
- Studying novel inhibitors of skin inflammation in lupus erythematosus
- Monitoring patient‑reported outcomes for skin symptom relief
Dermatology experts at the institute provide specialized assessments and imaging support.
Physiological Processes
Research emphasizes underlying biological mechanisms, using advanced imaging and biomarker analysis to understand disease progression in neuro‑ and immunologic conditions.
- Quantitative MRI studies of brain atrophy in progressive multiple sclerosis
- Gene‑expression profiling to track interferon signatures in skin disease
- Pharmacodynamic assessments of novel compounds on central nervous system inflammation
The site’s laboratory capabilities enable high‑resolution evaluation of physiological changes during treatment.
Mental Disorders
Trials target cognitive and behavioral symptoms in dementia and related disorders, exploring agents that may reduce agitation, improve memory, and support daily functioning.
- Testing safety and efficacy of novel compounds for agitation in Alzheimer’s dementia
- Assessing cognitive outcomes of oral semaglutide in mild cognitive impairment
- Evaluating combined therapies for neuropsychiatric symptoms in early Alzheimer’s
Psychiatric assessment teams collaborate closely with neurology to capture nuanced mental health endpoints.
Unspecified / Multidisciplinary Studies
A number of investigations span several therapeutic categories, such as migraine prevention, chronic pain, and spasticity, reflecting the institute’s flexible approach to emerging medical needs.
- Comparative studies of oral versus injectable migraine prophylaxis
- Evaluation of medical cannabis aerosol for neuropathic pain relief
- Dose‑response trials of new agents for chronic low‑back pain when standard options fail
- Safety and tolerability assessments of innovative botulinum toxin formulations across multiple indications
The multidisciplinary team at Instytut Zdrowia Dr Boczarska‑Jedynak adapts protocols to address patient‑centered outcomes across diverse conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 41 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Ipsen Innovation2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ipsen Innovation5trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instytut Zdrowia Dr Boczarska-Jedynak
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 44 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atogepant | 3 | Unknown | 2024-01-17 | 2025-03-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.